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STUDY AIM
To use a computational approach to identify connect BALT patients afflicted with COVID-19 to clinical trials to overcome
access limitations.

METHODS
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RESULTS
PubMed Abstract
EBI Accession Code
We used the dataset of the SWIFT-DIRECT Q16553: Lymphocyte Antigen 6E
trial, which randomized 408 patients to
IVT+MT or MT alone. Potential interactions
between assignment to IVT+MT and expected
time from onset-to-needle (OTN) as well as
expected time from door-to-needle (DTN)
were included in regression models. The
primary
outcome
was
functional
independence (modified Rankin Scale (mRS)
0-2) at 3 months. Secondary outcomes
included mRS shift, mortality, recanalization
rates,
and
(symptomatic)
intracranial
hemorrhage at 24 hours.

ClincialTrials.gov Summary
Immunotherapy based on Adoptive Cellular Transfer (ACT) uses several types
of immune cells, including dendritic cells, cytotoxic T lymphocytes, lymphokineactivated killer cells, and NK cells. NK cell-based immunotherapies are an
attractive approach for treating diseases because of their characteristic
recognition and killing mechanisms; they are involved in the early defense
against infectious pathogens and against MHC class-I-negative or -lowexpressing targets without the requirement for prior immune sensitization of
the host and are able to lyse target through the release of perforin and
granzymes and using antibody-dependent cellular cytotoxicity pathways
mediated by Fc receptor for IgG (CD16). The aim of this project is to evaluate
the safety and immunogenicity of allogeneic NK cells from peripheral blood
mononuclear cells (PBMCs) of healthy donors in patients infected with COVID19 collected by apheresis. This allows us to collect cGMP PBMCs and
immunomagnetic remove several types of undesirable cells including B, T and
CD33+ cells with enrichment of NK cells that will be expanded in bioreactors
with GMP culture media (AIM-V) supplemented with human AB serum and
GMP grade IL-2, and IL-15. After quality control verification the final NK cell
product will be resuspended in 300 mL saline solution for intravenous infusion.
Initially, we will enroll in this study ten COVID-19 infected adult patients with
moderate symptoms (NEWS 2 scale score>4). Consent forms will be signed
by the patient before the therapy. Patients will be treated with three different
infusions of NK cells 48 h apart with 1, 10, and 20 million cells/kg body weight.
We will follow the patients for any adverse effect, clinical response and
immune effects by flow cytometry including markers for NK cells expressing
different markers (CD158b, NKG2A, and IFN-y). We anticipated that the
release of IFN-y by exogenous NK cells could attract other immune cell
populations to boost the immune response against COVID-19.
NCT04344548

CONCLUSION & FUTURE DIRECTIONS

• This platform can serve as a medium to improve access by connecting
patients to active clinical trials.
• Connect patients to active clinical trials globally.
• Form relationships with EMR organizations and integrate this platform to
improve access & quality of care.

